Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Small Lymphocytic Lymphoma
Related studies linked through entity extraction aliases.
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
- Status
- COMPLETED
- Phase
- PHASE2
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
- Status
- TERMINATED
- Phase
- PHASE2
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
- Status
- TERMINATED
- Phase
- PHASE1
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Allo HSCT Using RIC for Hematological Diseases
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
- Status
- WITHDRAWN
- Phase
- PHASE1
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
- Status
- WITHDRAWN
- Phase
- PHASE3
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
- Status
- COMPLETED
- Phase
- PHASE2